Do Pharmacy Intervention Reports Adequately Describe Their Interventions? A Template for Intervention Description and Replication Analysis of Reports included in a Systematic Review by de Barra, Micheal et al.
1de Barra M, et al. BMJ Open 2019;9:e025511. doi:10.1136/bmjopen-2018-025511
Open access 
Do pharmacy intervention reports 
adequately describe their interventions? 
A template for intervention description 
and replication analysis of reports 
included in a systematic review
Mícheál de Barra   ,1,2 Claire Scott,2,3 Marie Johnston,2 M De Bruin,2,4 Neil Scott,2 
Catriona Matheson,5 Christine Bond,2 Margaret Watson   2,6
To cite: de Barra M, Scott C, 
Johnston M, et al.  Do pharmacy 
intervention reports adequately 
describe their interventions? 
A template for intervention 
description and replication 
analysis of reports included in 
a systematic review. BMJ Open 
2019;9:e025511. doi:10.1136/
bmjopen-2018-025511
 ► Prepublication history and 
additional material for this 
paper are available online. To 
view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2018- 
025511).
Received 19 July 2018
Revised 28 May 2019
Accepted 25 June 2019
For numbered affiliations see 
end of article.
Correspondence to
Dr Mícheál de Barra;  
 micheal. debarra@ brunel. ac. uk
Original research
© Author(s) (or their 
employer(s)) 2019. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published by 
BMJ.
AbstrACt
Introduction Scientific progress and translation of 
evidence into practice is impeded by poorly described 
interventions. The Template for Intervention Description 
and Replication (TIDieR) was developed to specify the 
minimal intervention elements that should be reported.
Objectives (1) To assess the extent to which outpatient 
pharmacy interventions were adequately reported. (2) To 
examine the dimension(s) across which reporting quality 
varies. (3) To examine trial characteristics that predict 
better reporting.
Methods The sample comprised 86 randomised 
controlled trials identified in a Cochrane review of the 
effectiveness of pharmacist interventions on patient 
health outcomes. Duplicate, independent application of 
a modified 15- item TIDieR checklist was undertaken to 
assess the intervention reporting. The reporting/non- 
reporting of TIDieR items was analysed with principal 
component analysis to evaluate the dimensionality of 
reporting quality and regression analyses to assess 
predictors of reporting quality
results In total, 422 (40%) TIDieR items were fully 
reported, 395 (38%) were partially reported and 231 (22%) 
were not reported. A further 242 items were deemed not 
applicable to the specific trials. Reporting quality loaded on 
one component which accounted for 26% of the variance 
in TIDieR scores. More recent trials reported a slightly 
greater number of TIDieR items (0.07 (95% CI 0.02 to 
0.13) additional TIDieR items per year of publication). Trials 
reported an 0.09 (95% CI 0.04 to 0.14) additional TIDieR 
items per unit increase in impact factor (IF) of the journal 
in which the main report was published.
Conclusions Most trials lacked adequate intervention 
reporting. This diminished the applied and scientific value 
of their research. The standard of intervention reporting 
is, however, gradually increasing and appears somewhat 
better in journals with higher IFs. The use of the TIDieR 
checklist to improve reporting could enhance the utility 
and replicability of trials, and reduce research waste.
bACkgrOund
Effective and efficient healthcare depends 
on trials in which the benefits and harms of 
interventions are experimentally assessed.1 
Underspecification of interventions hampers 
both implementation of evidence- based prac-
tice in healthcare settings and scientific prog-
ress.2–5 While additional detail and clarity 
could be derived, for example, by contacting 
study authors, this places additional and 
unnecessary burden on reviewers, researchers 
and other users of this information.2 6
If interventions are underspecified, meth-
odological decisions and results can be diffi-
cult to understand, evaluate and synthesise. 
Likewise, replication of interventions will be 
impossible if basic intervention characteristics 
like, for example, the frequency of interac-
tion between healthcare worker and patient, 
is not presented. Without clear descriptions 
of interventions, the similarities and differ-
ences between interventions will be obscured 
and this will hinder research synthesis in 
systematic reviews and meta- analyses. Thus, 
inadequate description of interventions is an 
important potential source of waste within 
biomedical research.7
strengths and limitations of this study
 ► We examined reporting quality in 86 trials of pharma-
cy interventions using the Template for Intervention 
Description and Replication (TIDieR).
 ► Multiple regression on TIDieR scores illuminated the 
predictors of good intervention reporting.
 ► A principal component analysis was used to explore 
the dimensionality of the TIDieR.
 ► Suboptimal inter- rater reliability of TIDieR assess-
ments suggest some subjectivity in our assessments.
 ► We made various assumptions (eg, journal impact 
factors are stable over time) to create predictor vari-
ables for the regression analyses.
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What is adequate reporting of an intervention? 
Hoffmann et al3 sought to answer this question using 
recommended consensus procedures8 including liter-
ature searches, a Delphi procedures and a face- to- face 
consensus meeting. The outcome was a checklist of 12 
items to be included in the description of interventions. 
This Template for Intervention Description and Replication 
(TIDieR) is included in the Equator portfolio of checklists 
and guides, which are intended to enhance the reporting 
of trials and research more broadly.9
TIDieR also provides a basis for evaluating reporting in 
the published literature. To our knowledge, three studies 
have evaluated interventions reported in randomised 
controlled trials (RCTs) using an adapted version of 
TIDieR.4–6 Abell et al6 found that just 8% (6/74) of 
exercise- based cardiac rehabilitation intervention reports 
described the core TIDieR elements deemed to be essen-
tial for replication, though this increased to 43% once 
additional sources were examined and the trial authors 
were contacted. Jones et al5 reported that 1% (1/100) 
of perioperative care interventions included all TIDieR 
items and that, on average, 43% of TIDieR items were 
omitted. In physiotherapy interventions evaluated by 
Yamato et al,4 23% (46/200) omitted more than half of 
TIDieR items.
Other studies of pharmacy interventions have used the 
Descriptive Elements of Pharmacist Intervention Char-
acterisation Tool (DEPICT10) tool. DEPICT is a check-
list developed to identify key components of pharmacy 
interventions and is intended as both a writing guide for 
pharmacists seeking describe their interventions in clear 
and replicable manner, and as a tool for retrospective 
analysis of interventions in the published literature. Thus, 
the rationale and utility of TIDieR and DEPICT overlap 
substantially. Studies using DEPICT to evaluate reporting 
quality found 59% of chronic kidney disease interven-
tions11 and ‘most’ asthma trials12 were not implementable 
based on the available intervention descriptions.
The focus of our study was on interventions imple-
mented by pharmacists in outpatient settings. In recent 
years, the pharmacist’s role has changed substantially in 
many countries, with a move away from the traditional 
function of medicine supply to more behavioural/clin-
ical roles. Pharmacists contribute to the safe and effective 
use of medicines through the delivery of services such as 
medication review,13 14 adherence support and advice to 
prescribers as well as enhanced roles in public health.15 
To maximise the efficient use of resources, service devel-
opment should be informed by research evidence and 
this is reflected in the growing number of RCTs of phar-
macist interventions.16 17 However, the value of these 
RCTs for policy and practice is dependent on the quality 
of reporting of the trial and complete descriptions of the 
interventions tested.
The first aim of our study was to evaluate the reporting 
of intervention descriptions in RCTs of pharmacy inter-
ventions using a modified TIDieR checklist. Our use of 
TIDieR rather than DEPICT enabled comparison with 
reporting quality in other health domains. A second 
aim was to examine how TIDieR items covaried, exam-
ining the dimensionality of TIDieR using a principal 
component analysis (PCA). This enabled us to analyse 
underlying patterns of TIDieR inclusion and exclusion 
by examining what items tend to co- occur or cluster in 
intervention descriptions. Such a pattern of covariation 
between TIDieR items would suggest that groups of indi-
vidual items reflect underlying dimension(s) of reporting 
quality. In other words, the PCA enabled us to investigate 
whether there was a subset of items which trials tend to 
report generally well or generally poorly. Identifying these 
dimensions could be useful since different dimensions of 
reporting quality may have unique and potentially modi-
fiable causes.
The final aim was to explore whether other article and 
journal characteristics predicted the completeness of 
intervention description. We aimed to examine whether 
reporting improved over time or was associated with 
other measures of quality, namely risk of bias (RoB). We 
explored the relationship between reporting quality and 
journal prestige, measured by the impact factor (IF). 
Although higher IF journals are often expected to publish 
‘better’ science, it is unclear if the reporting quality is 
superior. We examined if trial size (ie, number of partic-
ipants) was associated with completeness of intervention 
reporting. We also examined if reporting space predicts 
clearer reporting by examining (1) if trials described in 
multiple manuscripts reported interventions more clearly 
and (2) if reports published in journals with higher word 
limits reported interventions more clearly. The space- 
related predictor variables were added following reviewer 
recommendations. The other predictors were agreed by 
the author team before the results were known.
MethOds
A protocol for the study has not been published elsewhere.
trial report selection
Eighty- six published trial reports (online additional 
file 1A) were identified in an interim update of a 
Cochrane review of non- dispensing outpatient phar-
macy services17 and provided the data source for our 
study. Non- dispensing interventions aim to improve 
patient’s medication use (through, eg, education) 
or practitioner prescribing (through, eg, medication 
reviews). These trials were published between 1979 
and 2015, inclusive, and the median year of publica-
tion was 2010. Sixty- six of the trials precede 2014, the 
publication year of TIDieR checklist.3 The Cochrane 
review included RCTs which evaluated interventions 
to improve patient health in non- hospitalised patients 
through the use or cessation of medication and which 
were led or primarily delivered by a pharmacist. The 
search terms used to identify these trials are included in 
online additional file 1B (see also de Barra et al17) and 
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box 1 tIdier checklist adapted for report evaluation
Adapted tIdier items
1. Brief name. Provides the name or a phrase that describes the 
intervention.
2a. Why (clinical). Describes clinical rationale, theory or goal of the ele-
ments essential to the intervention.
2b. Why (behavioural). Describe behavioural rationale, theory or goal of 
the elements essential to the intervention theory, or goal of the elements 
essential to the intervention.
3. What (materials). Describes any physical or informational materials 
used in the intervention.
4. What (procedures). Describe each of the procedures, activities and/
or processes used in the intervention, including any enabling or support 
activities.
5a. Who (expertise). For each category of intervention provider, de-
scribes their expertise.
5b. Who (qualifications). For each category of intervention provider, de-
scribe their background.
5c. Who (training). For each category of intervention provider, describe 
specific training given.
6. How (delivery mode). Describe the modes of delivery (such as face- 
to- face or by some other mechanism, such as internet or telephone) of 
the intervention and whether it was provided individually or in a group.
7. Where (locations). Describe the type(s) of location(s) where the in-
tervention occurred, including any necessary infrastructure or relevant 
features.
8. When and how much. Describe the number of times the intervention 
was delivered and over what period of time including the number of 
sessions, their schedule, and their duration, intensity or dose.
9. Tailoring. If the intervention was planned to be personalised, titrated 
or adapted, then describe what, why, when and how.
10. Modifications. If the intervention was modified during the course of 
the trial, describe the changes (what, why, when and how).
11. How well (planned). If intervention adherence or fidelity was as-
sessed, describe how and by whom, and if any strategies were used to 
maintain or improve fidelity, describe them.
12. How well (actual). If intervention adherence or fidelity was assessed, 
describe the extent to which the intervention was delivered as planned.
See online additional file 1C for full scoring criteria.
TIDieR, Template for Intervention Description and Replication.
a Preferred Reporting Items for Systematic Reviews and 
Meta- Analyses checklist is available in online additional 
file 2.
tIdier reporting
The 12- item TIDieR checklist was adapted by subdividing 
several items prior to its application in this study. Note 
that these modifications are intended to facilitate TIDi-
eR’s use for the evaluation of published intervention 
descriptions and should not be construed as an attempt 
to modify of TIDieR more generally. One item, ‘why: 
rationale of the intervention’, was split into two sepa-
rate items. First, a behavioural rationale item was used 
to assess whether the authors presented any rationale or 
theory to justify behavioural components. For example, 
the introduction of a daily pill box might be justified 
by referring to studies which show that forgetfulness 
lowers adherence. Second, a clinical rationale item was 
used to assess if the pharmacological component of the 
intervention had been justified. The checklist item ‘who: 
provider training/experience’ was specified using three 
items: intervention- specific training described; qualifica-
tion of provider; and experience of provider. Definitions 
were created to specify when all items should be coded as 
‘included’, ‘partially included’ or ‘not included’. Thus, 
the 12- item checklist was developed into a 15- item evalua-
tion tool (box 1; scoring criteria provided in online addi-
tional file 1C). This tool was applied by two independent 
coders to assess the reporting of the interventions for the 
86 trials.
If reports made no mention of modification or fidelity/
adherence assessment (items 10, 11 and 12 in Box 1), we 
assumed that these reports described trials without modi-
fication or adherence assessment and coded the relevant 
item as ‘non- applicable’. These items were also excluded 
from composite scores (see Predicting TIDieR reporting 
rate below). It should be noted that TIDieR checklist does 
not require authors to report on such modifications/
adherence assessment if none occur.
The 15- item evaluation tool was iteratively developed by 
three authors and piloted on five papers. Once the tool 
was finalised, these papers were re- evaluated. Disagree-
ments were resolved through discussion between the two 
coders and, where necessary, consultation with a third 
coder. The inter- rater reliability of TIDieR coding was 
examined using Cohen’s kappa with squared weights.18 
TIDieR item presence and absence rates are presented 
descriptively.
dimensionality of tIdier
To investigate the dimensions of variability in TIDieR, 
a PCA19 was conducted on a Spearman’s correlation 
matrix of associations between TIDieR items. PCAs assess 
if different linear combinations of TIDieR variables 
summarise reporting quality using fewer variables. The 
number of components was determined using a parallel 
analysis.20 No rotation was performed.
Predicting tIdier reporting rate
To generate composite scores for the multivariate anal-
ysis, we summed the number of items reported and, sepa-
rately, the number of items not reported. This avoided the 
assumption of equidistance between included, partially 
included and not included. Another composite score 
was generated from the PCA results. Items that loaded 
on only one component at 0.6 or above (a threshold 
of ‘practical significance’21) were identified. We then 
created a weighted summed score by adding the weights 
of TIDieR items which met this criterion. Items were 
weighted as follows: not included=0, partly included=1 
and included=2. While this does assume equidistance, the 
psychometric/variable- reduction approach outlined here 
enables the identification and measurement of different 
dimensions of reporting quality.
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Journal IF was derived from Journal Citation Reports 
via the Web of Science citation indexing service.22 As in 
Dechartes et al,23 estimates were taken from the year 2016 
rather than the year of publication. Ten IFs were unavail-
able because the journal had been discontinued. We 
therefore assumed that these journals were likely to have 
low IF and hence we imputed these 10 missing values 
with the minimum IF of the extant journals included. 
The analyses were repeated excluding these 10 to test the 
robustness of findings.
Similarly, contemporary journal word limits rather than 
word limits at publication year were used as these could 
not feasibly be accessed. Where journals had no word 
limit used the maximum word limit found in the jour-
nals with a limit (10 000 words). Where journal word limit 
was impossible to determine, we used the median limit 
(3500 words). Where journals had multiple word limits 
(eg, short article vs main article), we used the limit for the 
main empirical articles.
RoB was estimated using the Cochrane RoB tool which 
evaluates bias on seven criteria.24 Two authors inde-
pendently applied the measure and resolved discrepan-
cies through discussion with a third author. Unclear RoB 
and high RoB scores are the number of criteria which were 
graded as unclear RoB or high RoB, respectively (possible 
range for both variables: 0–7). For further information on 
RoB in these trials, see the associated Cochrane Review.17
A multivariate regression was performed on each of the 
dependent variables (number of TIDieR items reported, 
number of TIDieR items not reported, PCA score(s)). 
Given that items 10–12 in box 1 were typically non- 
applicable, these were excluded from calculation of the 
‘TIDieR items reported’ and ‘TIDieR items not reported’ 
dependent variables. The following independent variables 
were included: (1) year of publication, to test for trend 
over time; (2) total sample size at baseline, to examine 
whether more complete reporting occurred with larger 
sample size; (3) IF, to examine whether trials published 
in more prestigious journals were better reported; (4) 
high RoB, to assess whether trials with other deficits were 
more likely to omit TIDieR items, (5) number of manu-
scripts, to assess if trials described in multiple manuscripts 
were better reported, and (6) word limit in publication 
journal, to assess if journal limits were associated with 
poorer reporting.
Correlation between different types of poor reporting
Additional correlation analyses focused on the relation-
ship between TIDieR items included/excluded and 
unclear RoB. These were analysed in a correlation anal-
ysis rather than the regression equations because unclear 
RoB can also be considered to be an additional measure 
of reporting quality rather than a possible cause of poor 
reporting.
Patient and public involvement
We assumed that patients and public favour complete 
reporting of interventions since such reporting patterns 
may both increase the quality of healthcare and decrease 
research waste and costs. Thus, there was no patient or 
public involvement in this study.
results
Inter-rater reliability of tIdier scoring
Cohen’s kappa with squared weights,18 which takes into 
account the ordinal nature of the data was 0.5, which 
represents a fair/moderate level of agreement.25 When 
items scored as non- applicable were included as an addi-
tional category, kappa increased to 0.73. The differences 
between coders typically lay in deciding if items were 
reported versus partially reported, or between not reported and 
partially reported.
tIdier reporting
There were 1290 items that could have been reported 
within this review (86 trials and 15 items/trial). Of these, 
422 (40%) were reported, 395 (38%) were partially 
reported and 231 (22%) items were not reported. The 
remaining 242 items were scored as non- applicable. No 
trials fully reported all 15 items.
The mean number of TIDieR items included in each 
trial was 4.83 (SD: 1.92), possible range 0 to 12This mean 
score excludes items 10–12 which were typically rated 
as non- applicable. The mean number of TIDieR items 
not reported was 2.65 (SD: 1.55). As figure 1 illustrates, 
substantial differences in reporting frequency occurred 
between items as well as between trials.
dimensionality of tIdier
A Spearman’s correlation plot (online additional file 1D) 
indicated some covariation in TIDieR items. Bartlett’s test 
of sphericity indicated that the data were suitable for PCA 
(χ2 (66)=165.77, p<0.001) and the Kaiser- Meyer- Olkin 
test26 suggested reasonable (0.75) sampling adequacy. 
A parallel analysis, executed with the paran package in 
R, indicated that one factor should be extracted. A scree 
plot, which includes the random data- derived eigenvalues 
produced by the parallel analysis, can be seen in online 
additional file 1D. The first four eigenvalues were 3.1, 
1.32, 1.25 and 1.14. Table 1 shows the factor loadings. 
This component accounted for 26% of the variance in 
TIDieR scores.
Scores (not included=0, partially=1, included=2) on the 
four items with loadings of 0.6 or higher were summed to 
produce a PCA- derived dependent variable with a Cron-
bach’s alpha of 0.72.
Predicting tIdier reporting rate
In all regression analyses, residual plots (linearity and 
homoscedasticity), QQ plots (normal errors) and the 
Durbin- Waton test (correlated errors) indicated that the 
assumptions of linear regression analyses were met; see 
online additional file 1E. Note that regression analyses 
which excluded the 10 reports with imputed IFs, show 
similar results.
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Figure 1 Top panel shows the proportion of TIDieR items 
not/partly or fully included in each of the 86 trial reports. Each 
bar represents one trial. Bottom panel shows the proportion 
of trials reports which report each of the 15 TIDieR items fully, 
partly or not at all. Three TIDieR items (13–15) were frequently 
scored non applicable. Each bar represents one TIDieR item. 
TIDieR,Template for Intervention Description and Replication.
Table 1 Component loadings for principle component 
analysis. Items in bold form the component measure
Component loading
Brief_name 0.02
Why_clinical 0.47
Why_behavioural 0.60
What_materials 0.72
What_procedure 0.74
Who_experience −0.38
Who_qualifications 0.25
Who_training 0.01
How_delivery_mode 0.66
Where_locations 0.24
When_how_much 0.58
Tailoring 0.64
The multiple regression analyses indicated an increase 
of 0.07 (95% CI 0.02 to 0.13) TIDieR items reported per 
year. For each additional unit of IF, 0.09 (95% CI 0.04 to 
0.14) extra TIDieR items were included. The pattern of 
association with TIDIeR items not included and with PCA 
component scores was broadly similar, see table 2. The 
regression predicting the PCA component indicated that 
larger trials may be more poorly reported (beta=−0.08, 
95% CI −0.14 to 0.02), though this pattern was not 
observed in the other two regressions. High RoB was not 
associated with TIDieR reporting.
Correlation between different kinds of poor reporting
Trials with fewer uncertain RoB evaluations reported 
more TIDieR items (r=−0.24, p= 0.03) and a higher 
TIDieR component score (r=−0.23, p= 0.03). The rela-
tionship between uncertain RoB and TIDieR items not 
included was in the predicted direction but not statisti-
cally significant (r= 0.15, p= 0.15).
dIsCussIOn
These results indicate (1) that more than half of TIDieR 
items were not fully included in pharmacy trial reports, 
(2) that variability in TIDieR reporting can be captured 
by a single component and (3) that slight improvements 
are being achieved over time, and that trials with more 
complete reporting are more likely to be published 
in higher impact journals. Number of manuscripts or 
journal word limits did not predict reporting quality.
Frequency of reporting of tIdier items
It is of concern that few intervention procedures were 
described with ‘sufficient detail for replication’ (a crite-
rion for item 4, what: procedures). The interventions were 
complex and involved varied interactions with patients, 
yet the description of these interventions was typically 
brief, often comprising only a single paragraph or a few 
sentences.27–30
Procedural ambiguity was also apparent in low scores 
for item 9, tailoring. Interventions were typically tailored 
to the clinical, knowledge or behavioural situation of the 
patient, yet in most cases the nature of this tailoring was 
not made explicit as an ‘if- then’ rule. Rather, this was 
left to the judgement and clinical skills of the pharma-
cist. While this is likely to reflect daily practice, ambiguity 
could be attenuated by being explicit about the back-
ground, experience and training—including training 
evaluation—of those employing their clinical judgement. 
Such information would enable the reader to understand 
what clinical competencies are necessary to implement 
these behaviour change interventions in a comparable 
fashion.31 However, with few exceptions,32–34 trial reports 
were not fully explicit about the experience, qualifica-
tions and training of personnel.
The majority of trials included some mention of 
materials but a detailed description of the package of, 
for example, questionnaires or educational booklets 
supplied to each pharmacy was typically lacking. While 
the frequency of interventions was generally described, 
the duration was often not made explicit.35–38 In their 
evaluation of cardiac rehabilitation interventions, Abell et 
al6 also found that session frequency was reported more 
often than session duration. The fidelity at which the 
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Table 2 Results of regression analyses predicting TIDieR scores
Number included Number not included PCA component 1
Constant 4.11 (2.88 to 5.34) 3.48 (2.43 to 4.53) 3.80 (2.63 to 4.97)
Year of publication 0.07 (0.02 to 0.13) −0.06 (−0.10 to –0.01) 0.04 (−0.01 to 0.10)
Sample size (per 100) −0.06 (−0.12 to 0.01) 0.05 (−0.01 to 0.10) −0.08 (−0.14 to −0.02)
Impact factor 0.09 (0.04 to 0.14) −0.02 (−0.07 to 0.02) 0.05 (−0.00 to 0.10)
Word limit (per 1000) 0.12(−0.05 to 0.29) −0.02 (−0.17 to 0.12) 0.11 (−0.06 to 0.27)
Papers per trial 0.19 (−0.46 to 0.83) −0.45 (−1.00 to 0.10) 0.21 (−0.40 to 0.83)
High risk of bias −0.06 (−0.45 to 0.34) −0.12 (−0.46 to 0.21) 0.07 (−0.30 to 0.45)
R- squared 0.26 0.17 0.18
F 0.59 2.77 2.98
P value 0.00 0.02 0.01
N 86 86 86
Betas in square brackets are 95% CIs.
TIDieR, Template for Intervention Description and Replication.
intervention was delivered was rarely mentioned, perhaps 
because this was rarely assessed. Although not the focus of 
this study, attention to the fidelity of intervention delivery 
may be important in explaining variability in effect size. 
In contrast to the clinical rationale, the behavioural ratio-
nale was reported less frequently. This requires a reason 
or theory for the selection of the proposed intervention 
and frameworks such as COM- B (capability, opportunity, 
motivation and behaviour)39 or the theoretical domain 
framework40 might be useful for future justification and 
reporting. In addition, the links between the proposed 
theoretical mechanism and the selected intervention 
could be specified.
Component structure of tIdier
In the present analysis, variation in quality of reporting 
was captured by a single dimension and this dimension 
accounted for approximately one- quarter of the vari-
ance in TIDieR scores. Items loading heavily on this item 
were what, how and why (behavioural) items. That is to 
say, trials tended to report these items generally well or 
generally poorly. For reasons unclear to us, variance in 
reporting who executed the intervention was less well 
captured by this component. Future research on the 
dimensional structure of TIDieR may benefit from larger 
sample sizes. With this in mind, the dataset associated 
with this study been placed online.41
What predicts reporting quality?
Trial reports published in higher impact journals tended 
to have better reporting quality. This trend is consistent 
with a recent analysis of unclear RoB evaluations in 20 
920 RCTs.23 Similarly, other studies have found a more 
general association between IF and methodological 
quality.42 43
Our results suggest an improvement in reporting quality 
over time, a result consistent with other studies.23 44 The 
rate of improvement is, however, very slow (0.8 additional 
items TIDieR items included per decade); time will tell 
if publication of TIDieR checklist, as well as evaluations 
similar to our study, will enhance the pace of improve-
ment. The positive correlation between included TIDieR 
items and the number of unclear RoB evaluations 
suggests that trial reports with thorough intervention 
descriptions also tend to have well- described methodolo-
gies and points to the convergent validity of our reporting 
of quality measures.
Improving reporting quality
These results add to growing literature on the limits of 
intervention descriptions in the pharmacy literature10–12 45 
and in other biomedical fields.3 We now suggest some 
practical steps that might be taken to improve the quality 
of reporting.
First, we suggest that trial authors use TIDieR and 
DEPICT checklists when designing, planning and 
reporting their intervention. Often, this projects data 
extractor’s initial impression that a report was thoroughly 
written was disproved once the checklist had been applied. 
Checklists simplify the writing process and prevent errors, 
much as checklists have done in other medical and non- 
medical domains.46
While we found no evidence that word limit/papers- 
per- trial predict reporting quality, it would be hasty to 
conclude these limits are irrlevant. If word limits are 
prohibitive, appendices or additional online materials 
should be considered, although the longevity of such 
resources has been questioned. Hoffmann et al47 found 
that several trials had placed materials online but the 
resources had not been maintained and had become inac-
cessible. Services such as Figshare48 and the Open Science 
Foundation49 enable materials—including video/audio 
files—to be shared and cited.
There is evidence to suggest that the use of checklists 
during peer review enhances reporting quality.50 The 
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quality of reporting is likely to increase if reviewers assess 
reports using the checklist and/or if authors are required 
to state that they have complied with checklist recom-
mendations. There may also be a role for journal editors 
in making TIDieR or DEPICT checklist a criterion for 
evaluation of manuscripts. Indeed, evidence from RCTs 
suggests that introducing guidelines to evaluate papers 
increases reporting quality.50 Editors and publishers may 
also facilitate improvements by either excluding methods 
sections from the article word counts or by facilitating the 
dissemination of intervention descriptions in accessible 
appendices.
limitations
Agreement between the coders was less than ideal; the 
coders sometimes found it difficult to identify rules 
that unambiguously distinguished included from partly 
included or not included. In their evaluation of physio-
therapy interventions, Yamato et al4 similarly found agree-
ment for many TIDieR items was suboptimal.
Unlike earlier studies4 6 but as in Jones et al5 we opted 
not to code control group ‘interventions’. Studies have 
demonstrated that intervention effects are a function 
of what happens in the control group, and thus inter-
pretation of effect size depends on understanding what 
happens in control groups.51 Nevertheless, our study 
focused on reporting of interventions and thus the focus 
was solely on intervention groups.
We used contemporary journal word limits and IFs 
rather than limits/IFs at the date of manuscript publica-
tion. We also imputed missing IFs and word limits. These 
decisions probably increase the chance of underesti-
mating effect sizes.
COnClusIOns
Most pharmacy trials reviewed here lacked adequate 
intervention reporting. This diminished the applied and 
scientific value of the research and may stymie improv-
ments in patient health. The standard of intervention 
reporting is, however, gradually increasing and appears 
somewhat better in journals with higher IFs. The use of 
TIDieR checklist to improve reporting could enhance 
the utility and replicability of trials, and reduce research 
waste.
Author affiliations
1Life Sciences, Brunel University London, Middlesex, UK
2The Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK
3Dental Clinical Effectiveness, NHS Education for Scotland, Dundee, UK
4Radboud University Medical Center, Radboud Institute for Health Sciences, 
Radboud, The Netherlands
5Faculty of Social Sciences, University of Stirling, Stirling, UK
6Department of Pharmacy & Pharmacology, University of Bath, Bath, UK
Contributors The idea of evaluating the trial reports using TIDieR comes from MJ; 
all authors contributed to the design. MidB and CS extracted the data, with support 
from MJ and MW. MidB performed the analysis with suggestions from MDB, MJ, 
NS, CB and CM. MidB wrote the manuscript with comments from all authors.
Funding Funding was provided by the Chief Scientist Office, grant number 
CZH/4/1041. MidB was also funded by the Professor Roy Weir Career Development 
Fellowship. MW was funded by a Health Foundation Improvement Science 
Fellowship.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
data availability statement Data are available in a public, open access repository. 
Here is the Open Science Foundation link for the dataset: https:// osf. io/ a9mpw/
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non- commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
OrCId ids
Mícheál de Barra http:// orcid. org/ 0000- 0003- 4455- 6214
Margaret Watson http:// orcid. org/ 0000- 0002- 8198- 9273
reFerenCes
 1 Cochrane A. Effectiveness and efficiency: Random reflections on 
health services. Cambridge University Press, 1972.
 2 Glasziou P, Meats E, Heneghan C, et al. What is missing 
from descriptions of treatment in trials and reviews? BMJ 
2008;336:1472–4.
 3 Hoffmann TC, Glasziou PP, Boutron I, et al. Better reporting of 
interventions: template for intervention description and replication 
(TIDieR) checklist and guide. BMJ 2014;348:g1687.
 4 Yamato TP, Maher CG, Saragiotto BT, et al. How completely are 
physiotherapy interventions described in reports of randomised 
trials? Physiotherapy 2016;102:121–6.
 5 Jones EL, Lees N, Martin G, et al. How well is quality improvement 
described in the perioperative care literature? A systematic review. Jt 
Comm J Qual Patient Saf 2016;42:196–AP10.
 6 Abell B, Glasziou P, Hoffmann T Reporting and replicating trials 
of exercise- based cardiac rehabilitation: do we know what 
the researchers actually did? Circ Cardiovasc Qual Outcomes 
2015;8:187–94.
 7 Chalmers I, Glasziou P. Avoidable waste in the production 
and reporting of research evidence. Obstetrics & Gynecology 
2009;114:1341–5.
 8 Moher D, Schulz KF, Simera I, et al. Guidance for developers of 
health research reporting guidelines. PLoS Med 2010;7:e1000217.
 9 Equator Netowk, 2017. Available: http://www. equator- network. org/
 10 Rotta I, Salgado TM, Felix DC, et al. Ensuring consistent reporting of 
clinical pharmacy services to enhance reproducibility in practice: an 
improved version of DEPICT. J Eval Clin Pract 2015;21:584–90.
 11 Salgado TM, Correr CJ, Moles R, et al. Assessing the 
implementability of clinical pharmacist interventions in patients 
with chronic kidney disease: an analysis of systematic reviews. Ann 
Pharmacother 2013;47:1498–506.
 12 Crespo- Gonzalez C, Fernandez- Llimos F, Rotta I, et al. Characterization 
of pharmacists' interventions in asthma management: a systematic 
review. J Am Pharm Assoc 2018;58:210–9.
 13 Lowrie R, Lloyd SM, McConnachie A, et al. A cluster randomised 
controlled trial of a pharmacist- led collaborative intervention to 
improve statin prescribing and attainment of cholesterol targets in 
primary care. PLoS One 2014;9:e113370.
 14 Bruhn H, Bond CM, Elliott AM, et al. Pharmacist- led management of 
chronic pain in primary care: results from a randomised controlled 
exploratory trial. BMJ Open 2013;3:e002361.
 15 Avery AJ, Rodgers S, Cantrill JA, et al. A pharmacist- led information 
technology intervention for medication errors (pincer): a multicentre, 
cluster randomised, controlled trial and cost- effectiveness analysis. 
The Lancet 2012;379:1310–9.
 16 Nkansah N, Mostovetsky O, Yu C, et al. Effect of outpatient 
pharmacists' non- dispensing roles on patient outcomes and 
prescribing patterns. Cochrane Database Syst Rev 2010;58.
 17 de Barra M, Scott CL, Scott NW, et al. Pharmacist services for non- 
hospitalised patients. Cochrane Database Syst Rev 2018;2.
 18 Cohen J. Weighted kappa: nominal scale agreement with 
provision for scaled disagreement or partial credit. Psychol Bull 
1968;70:213–20.
copyright.
 o
n
 January 7, 2020 at University of Aberdeen. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-025511 on 19 December 2019. Downloaded from 
8 de Barra M, et al. BMJ Open 2019;9:e025511. doi:10.1136/bmjopen-2018-025511
Open access 
 19 Abdi H, Williams LJ. Principal component analysis. Wiley 
Interdisciplinary Reviews: Computational Statistics 2010;2:433–59.
 20 Horn JL. A rationale and test for the number of factors in factor 
analysis. Psychometrika 1965;30:179–85.
 21 Hair JF, Black WC, Babin BJ, et al. Multivariate data analysis. Prentice 
hall Upper Saddle River, NJ, 1998.
 22 Web of Science. Web of science, 2017. Available: http:// apps. 
webofknowledge. com
 23 Dechartres A, Trinquart L, Atal I, et al. Evolution of poor reporting 
and inadequate methods over time in 20 920 randomised controlled 
trials included in Cochrane reviews: research on research study. BMJ 
2017;357.
 24 Higgins JP, Green S. Cochrane handbook for systematic reviews of 
interventions. John Wiley & Sons, 2011.
 25 Fleiss L, Levin B, Paik MC. The measurement of interrater 
agreement. In: Statistical methods for rates and proportions. John 
Wiley & Sons, 1981.
 26 Kaiser HF. An index of factorial simplicity. Psychometrika 
1974;39:31–6.
 27 Schneiderhan ME, Shuster SM, Davey CS. Twelve- month 
prospective randomized study of pharmacists utilizing point- of- care 
testing for metabolic syndrome and related conditions in subjects 
prescribed antipsychotics. The Primary Care Companion for CNS 
Disorders 2014;16.
 28 Malone DC, Carter BL, Billups SJ, et al. Can clinical pharmacists 
affect SF-36 scores in veterans at high risk for medication- related 
problems? Med Care 2001;39:113–22.
 29 Choe HM, Mitrovich S, Dubay D, et al. Proactive case management 
of high risk patients with type 2 diabetes mellitus by a clinical 
pharmacist: a randomised controlled trial. American Journal of 
Managed Care 2005;11:253–5.
 30 Castejón AM, Calderón JL, Perez A, et al. A community- based 
pilot study of a diabetes pharmacist intervention in Latinos: impact 
on weight and hemoglobin a1c. J Health Care Poor Underserved 
2014;24:48–60.
 31 Dixon D, Johnstone M. What competences are required to deliver 
behaviour change interventions: development of a health behaviour 
change competency framework. In submission.
 32 Hirsch JD, Steers N, Adler DS, et al. Primary care–based, 
pharmacist–physician collaborative medication- therapy management 
of hypertension: a randomized, pragmatic trial. Clin Ther 
2014;36:1244–54.
 33 Finley PR, Rens HR, Pont JT, et al. Impact of a collaborative care 
model on depression in a primary care setting: a randomized 
controlled trial. Pharmacotherapy 2003;23:1175–85.
 34 Simpson SH, Majumdar SR, Tsuyuki RT, et al. Effect of adding 
pharmacists to primary care teams on blood pressure control in 
patients with type 2 diabetes: a randomized controlled trial. Diabetes 
Care 2011;34:20–6.
 35 Charrois TL, McAlister FA, Cooney D, et al. Improving hypertension 
management through pharmacist prescribing; the rural Alberta 
clinical trial in optimizing hypertension (rural RxACTION): trial design 
and methods. Implementation Science 2011;6.
 36 Mahwi TO, Obied KA. Role of the pharmaceutical care in the 
management of patients with type 2 diabetes mellitus. Integr Pharm 
Res Pract 2013;4.
 37 López Cabezas C, Falces Salvador C, Cubí Quadrada D, et al. 
Randomized clinical trial of a postdischarge pharmaceutical care 
program vs regular follow- up in patients with heart failure. Farm Hosp 
2006;30:328–42.
 38 Lenander C, Elfsson B, Danielsson B, et al. Effects of a pharmacist- 
led structured medication review in primary care on drug- related 
problems and hospital admission rates: a randomized controlled trial. 
Scand J Prim Health Care 2014;32:180–6.
 39 Michie S, van Stralen MM, West R. The behaviour change wheel: 
a new method for characterising and designing behaviour change 
interventions. Implementation Science 2011;6.
 40 Michie S, Carey RN, Johnston M, et al. From theory- inspired to 
theory- based interventions: a protocol for developing and testing a 
methodology for linking behaviour change techniques to theoretical 
mechanisms of action. Annals of Behavioral Medicine 2018;52:501–12.
 41 de Barra M. Do pharmacy intervention reports adequately report their 
interventions? A TIDieR analysis, 2019.
 42 Lee KPet al. Association of Journal quality indicators with 
methodological quality of clinical research articles. JAMA 
2002;287:2805–8.
 43 Kuroki LM, Allsworth JE, Peipert JF. Methodology and analytic 
techniques used in clinical research: associations with Journal 
impact factor. Obstet Gynecol 2009;114:877.
 44 Reveiz L, Chapman E, Asial S, et al. Risk of bias of randomized trials 
over time. J Clin Epidemiol 2015;68:1036–45.
 45 Kennie NR, Schuster BG, Einarson TR. Critical analysis of the 
pharmaceutical care research literature. Ann Pharmacother 
1998;32:17–26.
 46 Gawande A. The checklist manifesto: How to get things right. Profile 
Books, 2010.
 47 Hoffmann TC, Erueti C, Glasziou PP. Poor description of non- 
pharmacological interventions: analysis of consecutive sample of 
randomised trials. BMJ 2013;347:f3755.
 48 Figshare. Figshare, 2017. Available: https:// figshare. com
 49 Open Science Foundation. Available: https://www. osf. io
 50 Cobo E, Cortés J, Ribera JM, et al. Effect of using reporting 
guidelines during peer review on quality of final manuscripts 
submitted to a biomedical Journal: masked randomised trial. BMJ 
2011;343:d6783.
 51 de Bruin M, Viechtbauer W, Hospers HJ, et al. Standard care quality 
determines treatment outcomes in control groups of HAART- 
adherence intervention studies: implications for the interpretation 
and comparison of intervention effects. Health Psychology 
2009;28:668–74.
copyright.
 o
n
 January 7, 2020 at University of Aberdeen. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-025511 on 19 December 2019. Downloaded from 
